CEPHALON/ALKERMES SIGN PACT TO DEVELOP VIVITREX.
Biotech Business › Vol. 18 Nbr. 8, August 2005
Linked as:
Extract
CEPHALON/ALKERMES SIGN PACT TO DEVELOP VIVITREX.
Cephalon, Inc. (Nasdaq: CEPH) and Alkermes, Inc. (Nasdaq: ALKS) have entered into an agreement to develop and commercialize Vivitrex (naltrexone long-acting injection) in the United States. Vivitrex is an investigational drug in development by Alkermes for the treatment of alcohol dependence. Alkermes submitted...
See the full content of this document
Sponsored links
